Literature DB >> 6661365

Serum alpha 1-acid glycoprotein and the binding of drugs in obesity.

I H Benedek, W D Fiske, W O Griffen, R M Bell, R A Blouin, P J McNamara.   

Abstract

Although clinically relevant, drug-protein interactions in the morbidly obese population have not been studied thoroughly. The objective of this study was to evaluate serum chemistry profiles and the degree of serum protein binding of propranolol, diazepam and phenytoin in the serum of four female, morbidly obese (greater than 190% of ideal body weight) and eight control female subjects. Serum triglyceride concentrations were higher and high-density lipoproteins were lower in the obese subjects than in the control group. Serum albumin and total protein concentrations in the obese were not different from controls. Unexpectedly, alpha 1-acid glycoprotein concentrations were doubled in the obese subjects (mean obese value 121 mg/100 ml vs 62.9 mg/100 ml for the control subjects). Obese subjects had a mean fraction unbound (fu) for propranolol of 0.086, which was significantly different from the controls (fu = 0.123). The binding of diazepam was decreased slightly in the obese subjects. The binding of phenytoin was similar in both groups. The altered serum chemistry of obesity may play a significant role in the drug management of the obese patient by altering drug-protein interactions.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6661365      PMCID: PMC1428326          DOI: 10.1111/j.1365-2125.1983.tb02258.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  19 in total

1.  Commentary: a physiological approach to hepatic drug clearance.

Authors:  G R Wilkinson; D G Shand
Journal:  Clin Pharmacol Ther       Date:  1975-10       Impact factor: 6.875

2.  Comparative pharmacokinetics of coumarin anticoagulants. XIV: relationship between protein binding, distribution, and elimination kinetics of warfarin in rats.

Authors:  A Yacobi; G Levy
Journal:  J Pharm Sci       Date:  1975-10       Impact factor: 3.534

3.  The disposition of propranolol. 3. Decreased half-life and volume of distribution as a result of plasma binding in man, monkey, dog and rat.

Authors:  G H Evans; A S Nies; D G Shand
Journal:  J Pharmacol Exp Ther       Date:  1973-07       Impact factor: 4.030

4.  Immunochemical quantitation of antigens by single radial immunodiffusion.

Authors:  G Mancini; A O Carbonara; J F Heremans
Journal:  Immunochemistry       Date:  1965-09

Review 5.  Disease-induced changes in the plasma binding of basic drugs.

Authors:  K M Piafsky
Journal:  Clin Pharmacokinet       Date:  1980 May-Jun       Impact factor: 6.447

6.  Increased plasma binding of quinidine after surgery: a preliminary report.

Authors:  D Fremstad; K Bergerud; J F Haffner; P K Lunde
Journal:  Eur J Clin Pharmacol       Date:  1976       Impact factor: 2.953

7.  Colorimetric micro-determination of free fatty acids in plasma.

Authors:  S Laurell; G Tibbling
Journal:  Clin Chim Acta       Date:  1967-04       Impact factor: 3.786

8.  Diabetes, blood lipids, and the role of obesity in coronary heart disease risk for women. The Framingham study.

Authors:  T Gordon; W P Castelli; M C Hjortland; W B Kannel; T R Dawber
Journal:  Ann Intern Med       Date:  1977-10       Impact factor: 25.391

9.  Obesity, lipids, and glucose intolerance. The Framingham Study.

Authors:  W B Kannel; T Gordon; W P Castelli
Journal:  Am J Clin Nutr       Date:  1979-06       Impact factor: 7.045

10.  Increased plasma protein binding of propranolol and chlorpromazine mediated by disease-induced elevations of plasma alpha1 acid glycoprotein.

Authors:  K M Piafsky; O Borgá; I Odar-Cederlöf; C Johansson; F Sjöqvist
Journal:  N Engl J Med       Date:  1978-12-28       Impact factor: 91.245

View more
  24 in total

Review 1.  Effect of diabetes mellitus on pharmacokinetic and pharmacodynamic properties of drugs.

Authors:  Miroslav Dostalek; Fatemeh Akhlaghi; Martina Puzanovova
Journal:  Clin Pharmacokinet       Date:  2012-08-01       Impact factor: 6.447

Review 2.  Disease-induced variations in plasma protein levels. Implications for drug dosage regimens (Part II).

Authors:  R Zini; P Riant; J Barré; J P Tillement
Journal:  Clin Pharmacokinet       Date:  1990-09       Impact factor: 6.447

Review 3.  Measurement and analysis of unbound drug concentrations.

Authors:  J D Wright; F D Boudinot; M R Ujhelyi
Journal:  Clin Pharmacokinet       Date:  1996-06       Impact factor: 6.447

4.  Prolongation of ifosfamide elimination half-life in obese patients due to altered drug distribution.

Authors:  M J Lind; J M Margison; T Cerny; N Thatcher; P M Wilkinson
Journal:  Cancer Chemother Pharmacol       Date:  1989       Impact factor: 3.333

5.  Incorporation of the Time-Varying Postprandial Increase in Splanchnic Blood Flow into a PBPK Model to Predict the Effect of Food on the Pharmacokinetics of Orally Administered High-Extraction Drugs.

Authors:  Rachel H Rose; David B Turner; Sibylle Neuhoff; Masoud Jamei
Journal:  AAPS J       Date:  2017-05-19       Impact factor: 4.009

6.  The plasma protein binding of basic drugs.

Authors:  P A Routledge
Journal:  Br J Clin Pharmacol       Date:  1986-11       Impact factor: 4.335

7.  Anesthetic Pharmacology and the Morbidly Obese Patient.

Authors:  Jerry Ingrande; Hendrikus Jm Lemmens
Journal:  Curr Anesthesiol Rep       Date:  2012-12-13

Review 8.  Drug disposition in obese humans. An update.

Authors:  D R Abernethy; D J Greenblatt
Journal:  Clin Pharmacokinet       Date:  1986 May-Jun       Impact factor: 6.447

9.  Does alpha 1-acid glycoprotein reduce the unbound metabolic clearance of disopyramide in patients with renal impairment?

Authors:  J Braun; F Sörgel; W P Gluth; S Oie
Journal:  Eur J Clin Pharmacol       Date:  1988       Impact factor: 2.953

Review 10.  Free drug concentration monitoring in clinical practice. Rationale and current status.

Authors:  C K Svensson; M N Woodruff; J G Baxter; D Lalka
Journal:  Clin Pharmacokinet       Date:  1986 Nov-Dec       Impact factor: 6.447

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.